Fusion protein AAFP

重组人免疫球蛋白ε和γ的Fc融合蛋白

Report date: 2023/12/16 20:00:45

Base Information

Drug NameFusion protein AAFP
Drug Alias NameFcɛ∼Fcγ fusion protein
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunomodulatorsIgE Fc receptor, alpha-subunit modulatorsLow affinity immunoglobulin gamma Fc region receptor II-b modulators
TargetsIgE Fc receptor, alpha-subunitLow affinity immunoglobulin gamma Fc region receptor II-b
Therapy Area/IndicationsAllergic asthmaAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Kexin Biomedical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Kexin Biomedical Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsAllergic asthmaAsthma

Other Information

ATC CodeN/A
Related LinksN/A